The clinical trial “Impact of Obesity on the Efficacy of Endocrine Therapy with Aromatase Inhibitors” (NCT01758146) is currently evaluating the efficacy of adjuvant tamoxifen compared with letrozole and should provide more information on endocrine therapy selection in this important population. Here, CYP19A1 is linked to obesity due to melanocortin 4 receptor deficiency.